Bausch + Lomb Corporation (BLCO)
BLCO Gains European CE Mark for Next-Gen SeeLyra Femtosecond Laser
Bausch + Lomb gains European CE Mark approval for SeeLyra, expanding its surgical portfolio with a compact laser platform for cataract and corneal procedures.
Bausch + Lomb Advances Two First-in-Class Eye Health Therapies
BLCO advances two eye-health candidates after positive trial results, with combined estimated peak sales exceeding $2 billion.
Bausch + Lomb Corporation (BLCO) Discusses Results and Development Plans for Dual Action Dry Eye Medicine and Lead Ocular Surface Pain Candidate Transcript
Bausch + Lomb Corporation (BLCO) Discusses Results and Development Plans for Dual Action Dry Eye Medicine and Lead Ocular Surface Pain Candidate Transcript
Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal
Bausch + Lomb NYSE: BLCO said it plans to advance a dual-action dry eye treatment into Phase III development after a Phase II study showed statistically significant improvement in corneal staining at day 15, although the trial did not meet its primary endpoint at day 29.
Bausch + Lomb Corporation (BLCO) Q2 2026 Earnings Call Transcript
Bausch + Lomb Corporation (BLCO) Q2 2026 Earnings Call Transcript
Bausch + Lomb Q2 Earnings Call Highlights
Bausch + Lomb NYSE: BLCO reported second-quarter 2026 revenue growth across its vision care, surgical and pharmaceutical businesses, while raising its full-year revenue and adjusted EBITDA outlook. The company said improved product mix, productivity initiatives and lower fixed-cost intensity supported margin expansion and stronger cash generation.
Bausch + Lomb (BLCO) Q2 Earnings Meet Estimates
Bausch + Lomb (BLCO) came out with quarterly earnings of $0.16 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.07 per share a year ago.
Bausch + Lomb Launches EyeGility Inserter for enVista IOLs in the U.S.
BLCO launches EyeGility in the United States, pairing preloaded enVista Aspire lenses with smoother handling, one-handed use and surgical flexibility.
Bausch + Lomb Corporation (BLCO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Bausch + Lomb Corporation (BLCO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Bausch + Lomb Corporation (BLCO) Discusses Project Halo and Myopia Control Developments in Vision Care Transcript
Bausch + Lomb Corporation (BLCO) Discusses Project Halo and Myopia Control Developments in Vision Care Transcript
Americans Are Cutting Spending on Everything Except Healthcare. These 2 Medical Device Stocks Under $30 Are Built to Win
With consumer sentiment sitting at 53.3 in March 2026, deep in pessimistic territory, retail investors are hunting for defensive names that can grow even as households tighten budgets.
Bausch + Lomb Corporation (BLCO) Q1 2026 Earnings Call Transcript
Bausch + Lomb Corporation (BLCO) Q1 2026 Earnings Call Transcript
